Radioiodine (131 1) targets thyroid tissues and has been an effective and standard treatment for differentiated thyroid cancers for many years. However, the Na +/| symporter (NIS), which mediates active iodide uptake into thyroid follicular cells, is also abundantly expressed in salivary ductal cells. Accordingly, many I-treated thyroid cancer survivors suffer from life-long morbidity of l-induced salivary gland (SG) dysfunction, including recurrent sialadenitis, persistent xerostomia, and progressive susceptibility to dental caries and periodontal disease. In this proposal, we aim to explore novel approaches to prevent I-induced SG damage in thyroid cancer patients, and to identify protective saliva biomarkers for patients'susceptibility to progressive I-induced SG dysfunction.
Two specific aims are identified: (1) Transient silencing/inhibition of salivary NIS to eliminate salivary """"""""^1 accumulation during radioiodine therapy;and (2) Identify protective saliva biomarkers and underlying pathobiology for I-induced SG dysfunction. Upon successful completion of the proposed studies, our novel prevention strategy promises to eliminate I-induced SG damage or at least dramatically reduce its occurrence among thyroid cancer survivors who will receive I therapy. We will be able to use quantifiable saliva biomarkers or SG anatomic changes to monitor the onset and progression of SG dysfunction induced by """"""""^1 such that personalized intervention strategies can be applied to patients in a timely manner. We will determine whether saliva biomarkers detected in the early stage of salivary dysfunction induced by I are predictive of future progression to chronic disease. We may also distinguish patients who are more susceptible or resistant to develop life-long morbidity of I-induced SG dysfunction for differential clinical management.

Public Health Relevance

Many thyroid cancer survivors treated with radioiodine suffer from life-long morbidity of 1-131 induced salivary gland dysfunction. The major goal of this proposal is to identify saliva biomarkers enabling personalized intervention of this adverse effect. In addition, we propose a novel prevention strategy with the hope to eliminate radioiodine induced salivary gland damage or at least dramatically reduce its occurrence among thyroid cancer patients treated with radioiodine.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA168505-01A1
Application #
8588546
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2013-09-25
Project End
2018-07-31
Budget Start
2013-09-25
Budget End
2014-07-31
Support Year
1
Fiscal Year
2013
Total Cost
$292,394
Indirect Cost
$78,895
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Liyanarachchi, Sandya; Li, Wei; Yan, Pearlly et al. (2016) Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis. J Clin Endocrinol Metab 101:4005-4013
Hollingsworth, Brynn; Senter, Leigha; Zhang, Xiaoli et al. (2016) Risk Factors of (131)I-Induced Salivary Gland Damage in Thyroid Cancer Patients. J Clin Endocrinol Metab 101:4085-4093
Justiniano, Steven E; McElroy, Joseph P; Yu, Lianbo et al. (2016) Genetic variants in thyroid cancer distant metastases. Endocr Relat Cancer 23:L33-6
Nabhan, Fadi; Ringel, Matthew D (2016) Thyroid nodules and cancer management guidelines: comparisons and controversies. Endocr Relat Cancer :
Shirley, Lawrence A; McCarty, Samantha; Yang, Ming-Chen et al. (2016) Integrin-linked kinase affects signaling pathways and migration in thyroid cancer cells and is a potential therapeutic target. Surgery 159:163-70
Danysh, Brian P; Rieger, Erin Y; Sinha, Deepankar K et al. (2016) Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Oncotarget 7:30907-23
Nagy, Rebecca; Ringel, Matthew D (2015) Genetic predisposition for nonmedullary thyroid cancer. Horm Cancer 6:13-20
Tomsic, Jerneja; He, Huiling; de la Chapelle, Albert (2015) HABP2 Mutation and Nonmedullary Thyroid Cancer. N Engl J Med 373:2086
He, Huiling; Li, Wei; Liyanarachchi, Sandya et al. (2015) Multiple functional variants in long-range enhancer elements contribute to the risk of SNP rs965513 in thyroid cancer. Proc Natl Acad Sci U S A 112:6128-33
He, Huiling; Li, Wei; Liyanarachchi, Sandya et al. (2015) Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2. J Clin Endocrinol Metab 100:E164-72

Showing the most recent 10 out of 18 publications